These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1106 related articles for article (PubMed ID: 22442268)

  • 81. No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma.
    Kumagai A; Namba H; Takakura S; Inamasu E; Saenko VA; Ohtsuru A; Yamashita S
    Endocr J; 2006 Oct; 53(5):615-20. PubMed ID: 16896265
    [TBL] [Abstract][Full Text] [Related]  

  • 82. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Expression of BRAF and its extracellular signal-regulated kinase 1/2 signal pathway in papillary thyroid cancer].
    Yi W; Zhong D; Zou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 37(9):889-94. PubMed ID: 23000762
    [TBL] [Abstract][Full Text] [Related]  

  • 84. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
    Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
    Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
    [TBL] [Abstract][Full Text] [Related]  

  • 85. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
    Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
    [TBL] [Abstract][Full Text] [Related]  

  • 86. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
    Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
    Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
    Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.
    Dultz LA; Dhar S; Ogilvie JB; Heller KS; Bar-Sagi D; Patel KN
    Surgery; 2013 Dec; 154(6):1239-44; discussion 1244-5. PubMed ID: 24094449
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI; Solit DB
    Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
    [TBL] [Abstract][Full Text] [Related]  

  • 92. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
    Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma.
    Bansal M; Gandhi M; Ferris RL; Nikiforova MN; Yip L; Carty SE; Nikiforov YE
    Am J Surg Pathol; 2013 Oct; 37(10):1586-91. PubMed ID: 23797723
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Pathogenesis of differentiated thyroid cancer (papillary and follicular)].
    Maciel RM; Kimura ET; Cerutti JM
    Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):691-700. PubMed ID: 16444351
    [TBL] [Abstract][Full Text] [Related]  

  • 95. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.
    Barone MV; Sepe L; Melillo RM; Mineo A; Santelli G; Monaco C; Castellone MD; Tramontano D; Fusco A; Santoro M
    Oncogene; 2001 Oct; 20(48):6973-82. PubMed ID: 11704822
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
    Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
    Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [The correlation between BRAF mutations, RET/PTC rearrangements and platelet-derived growth factor B expression in papillary thyroid carcinomas].
    Wang P; Wang YG; Zhao WJ; Fu YD; Wang L; Wang F; Zhao SH
    Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):987-91. PubMed ID: 23327964
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
    Schweppe RE; Kerege AA; Sharma V; Poczobutt JM; Gutierrez-Hartmann A; Grzywa RL; Haugen BR
    Thyroid; 2009 Aug; 19(8):825-35. PubMed ID: 19500021
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Intracellular signaling mechanisms in thyroid cancer].
    Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
    Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Genetic predictors of MEK dependence in non-small cell lung cancer.
    Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
    Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.